Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 10/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15201755 | 0.98 | TSHR (0.36) | TSHRTHRBSMPD1CES1FDPS | |
| Ammonia Solution, Strong SCHEMBL28650831 | 0.96 | TSHR (0.35) | TSHRTHRBSMPD1CES1FDPS | |
| SCHEMBL9750720 | 0.90 | TSHR (0.35) | TSHRTHRBSMPD1CES1FDPS | |
| SCHEMBL27805429 | 0.88 | TSHR (0.40) | TSHRTHRBSMPD1CES1FDPS | |
| SCHEMBL16448809 | 0.86 | HRH3 (0.32) | — | |
| SCHEMBL10147430 | 0.82 | LMNA (0.32) | TSHR | |
| SCHEMBL9451864 | 0.82 | TSHR (0.32) | TSHRTHRBCES1FDPS | |
| SCHEMBL13517303 | 0.81 | MEN1 (0.34) | TSHRTHRBSMPD1CES1FDPS | |
| SCHEMBL8533945 | 0.80 | DNM1 (0.37) | TSHRFDPSMEN1KMT2A | |
| SCHEMBL13517977 | 0.79 | MEN1 (0.37) | TSHRTHRBSMPD1CES1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | TSHR 4687/4885THRB 4251/4885SMPD1 448/4885 |
| US-20120039848-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | TSHR 4687/4885THRB 4251/4885SMPD1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.